The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
Tóm tắt
The coronavirus disease 2019 (COVID-19) pandemic created challenges related to disease management of patients with ulcerative colitis (UC). The UC Narrative COVID-19 survey was conducted from August to December 2021 among adults with UC from the United States, Canada, Japan, France, and Finland. Patients were questioned on disease management, health care access and experience, and preferences for interactions with their doctor. Data were analyzed descriptively. In total, 584 patients qualified for and completed the survey. Compared with 2019, 25% experienced more flares during the pandemic (from early 2020). Most patients (88%) taking prescription medication were very/somewhat satisfied with their current treatment plan; 53% were hesitant to make changes during the pandemic. Factors that patients agreed helped control UC symptoms during the pandemic included fewer social outings (37%), working from home (29%), and less busy schedules (28%). Greater anxiety/stress (43%) and hesitancy to visit a hospital/office (34%) made the control of UC symptoms more difficult. Compared with 2019, more patients relied on certain alternative support systems during the pandemic. Patients who used in-person and virtual appointments were equally very satisfied/satisfied with the quality of care (both 81%). In-person appointments were preferred by 68% of patients when meeting a new doctor, 55% when experiencing a flare, and 52% for regular check-ups; 41% preferred virtual appointments for UC prescription refills. During the pandemic, most patients were satisfied with their current UC treatment plan and access to care; more patients relied on certain alternative UC management support systems, and many were impacted by anxiety/stress.
The coronavirus disease 2019 (COVID-19) pandemic created challenges for patients with ulcerative colitis. These challenges included managing symptoms, lifestyle changes, and access to health care. We asked patients with ulcerative colitis to answer questions about their experience during the pandemic to try to understand how the pandemic was affecting them. A total of 584 patients from the United States, Canada, Japan, France, and Finland took part. Patients were asked questions online. We asked them about their disease activity during the COVID-19 pandemic compared with before the pandemic and how their disease was managed, their access to health care, and their experience during the pandemic. We also asked them about their satisfaction with the types of appointments they had during the pandemic (for example, in-person or virtual meetings), and their interactions and preference for interactions with their doctors. We found that most patients were satisfied with their current treatment plan, their access to health care, and the quality of the care they received. However, many patients experienced greater stress or anxiety, and there was a negative impact on their emotional well-being. During the pandemic, more patients relied on alternative support systems such as online patient portals or virtual appointments, but patients preferred in-person appointments with their doctors in most cases except for refilling prescriptions. This information may help doctors understand the impact of the COVID-19 pandemic on patients with ulcerative colitis, and may help doctors and patients develop treatment plans that include both in-person and virtual appointments.
Tài liệu tham khảo
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–70.
Jones JL, Nguyen GC, Benchimol EI, et al. The impact of inflammatory bowel disease in Canada 2018: quality of life. J Can Assoc Gastroenterol. 2019;2:S42–8.
Goodsall TM, Han S, Bryant RV. Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2021;36:1550–5.
Graff LA, Fowler S, Jones JL, et al. Crohn’s and colitis Canada’s 2021 impact of COVID-19 and inflammatory bowel disease in Canada: mental health and quality of life. J Can Assoc Gastroenterol. 2021;4:S46–53.
Jones JL, Benchimol EI, Bernstein CN, et al. Crohn’s and colitis Canada’s 2021 impact of COVID-19 and inflammatory bowel disease in Canada: health care delivery during the pandemic and the future model of inflammatory bowel disease care. J Can Assoc Gastroenterol. 2021;4:S61–7.
El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021;37:313–9.
Schreiber S, Ben-Horin S, Alten R, et al. Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era. Adv Ther. 2022;39:2342–64.
Vigano C, Mulinacci G, Palermo A, et al. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol. 2021;27:5520–35.
Dubinsky MC, Watanabe K, Molander P, et al. Ulcerative Colitis Narrative global survey findings: the impact of living with ulcerative colitis – a patients’ and physicians’ view. Inflamm Bowel Dis. 2021;27:1747–55.
Rubin DT, Hart A, Panaccione R, et al. Ulcerative Colitis Narrative global survey findings: communication gaps and agreements between patients and physicians. Inflamm Bowel Dis. 2021;27:1096–106.
Kish L. Survey sampling. New York: Wiley; 1965.
Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. 3rd ed. New York: Chapman and Hall/CRC; 2013.
Saibeni S, Scucchi L, Dragoni G, et al. Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: how to maintain standards of care. United European Gastroenterol J. 2020;8:1228–35.
Martin Arranz E, Suarez Ferrer C, García Ramírez L, et al. Management of COVID-19 pandemic in Spanish inflammatory bowel disease units: results from a national survey. Inflamm Bowel Dis. 2020;26:1149–54.
Allocca M, Fiorino G, Furfaro F, et al. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic. Clin Gastroenterol Hepatol. 2020;18:1882–3.
Nishida Y, Hosomi S, Fujimoto K, et al. Impact of the lockdown due to the COVID-19 pandemic on patients with inflammatory bowel disease. Front Med (Lausanne). 2021;8: 649759.
El-Dallal M, Saroufim A, Systrom H, et al. Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. Scand J Gastroenterol. 2022;57:406–14.
Kale A, Shinde L, Sundaram S, et al. COVID-19 pandemic and inflammatory bowel disease from patients’ perspective: a survey from COVID epicenter in India. JGH Open. 2022;6:126–31.
Kornbluth A, Kissous-Hunt M, George J, Legnani P. Management of inflammatory bowel disease and COVID-19 in New York City 2020: the epicenter of IBD in the first epicenter of the global pandemic. Inflamm Bowel Dis. 2020;26:1779–85.
Tian WN, Huang YH, Dai C. The effect of the COVID-19 pandemic on the medical mode of patients with inflammatory bowel disease in China. Inflamm Bowel Dis. 2020;26:e116–7.
Taxonera C, Alba C, Olivares D, Martin M, Ventero A, Canas M. Innovation in IBD care during the COVID-19 pandemic: results of a cross-sectional survey on patient-reported experience measures. Inflamm Bowel Dis. 2021;27:864–9.
Harris RJ, Downey L, Smith TR, Cummings JRF, Felwick R, Gwiggner M. Life in lockdown: experiences of patients with IBD during COVID-19. BMJ Open Gastroenterol. 2020;7: e000541.
Shah R, Wright E, Tambakis G, et al. Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic. Intern Med J. 2021;51:1038–42.
Stone ML, Feng M, Forster EM. COVID-19 pandemic increased anxiety among patients with inflammatory bowel disease: a patient survey in a tertiary referral center. Dig Dis Sci. 2021;67:2876–81.
Fiorino G, Allocca M, Furfaro F, et al. Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan, experience. J Crohns Colitis. 2020;14:1330–3.
DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175:1298–304.